Supernus Pharmaceuticals Inc (SUPN)
26.39
+0.40
(+1.54%)
USD |
NASDAQ |
Jun 17, 12:58
Supernus Pharmaceuticals Accounts Receivable (Quarterly): 147.73M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 147.73M |
December 31, 2023 | 144.16M |
September 30, 2023 | 141.76M |
June 30, 2023 | 136.56M |
March 31, 2023 | 143.57M |
December 31, 2022 | 165.50M |
September 30, 2022 | 164.09M |
June 30, 2022 | 158.06M |
March 31, 2022 | 145.15M |
December 31, 2021 | 148.93M |
September 30, 2021 | 133.68M |
June 30, 2021 | 137.28M |
March 31, 2021 | 127.06M |
December 31, 2020 | 140.88M |
September 30, 2020 | 133.11M |
June 30, 2020 | 126.56M |
March 31, 2020 | 119.20M |
December 31, 2019 | 87.33M |
September 30, 2019 | 86.70M |
June 30, 2019 | 84.56M |
March 31, 2019 | 79.95M |
December 31, 2018 | 102.92M |
September 30, 2018 | 77.75M |
June 30, 2018 | 74.84M |
March 31, 2018 | 67.86M |
Date | Value |
---|---|
December 31, 2017 | 65.59M |
September 30, 2017 | 56.17M |
June 30, 2017 | 51.16M |
March 31, 2017 | 38.88M |
December 31, 2016 | 41.53M |
September 30, 2016 | 36.22M |
June 30, 2016 | 34.28M |
March 31, 2016 | 30.65M |
December 31, 2015 | 25.91M |
September 30, 2015 | 23.60M |
June 30, 2015 | 17.90M |
March 31, 2015 | 19.27M |
December 31, 2014 | 17.27M |
September 30, 2014 | 15.30M |
June 30, 2014 | 10.85M |
March 31, 2014 | 9.725M |
December 31, 2013 | 5.054M |
September 30, 2013 | 7.208M |
June 30, 2013 | 0.537M |
March 31, 2013 | 1.65M |
December 31, 2012 | 0.011M |
September 30, 2012 | 0.50M |
June 30, 2012 | |
March 31, 2012 | |
December 31, 2011 | 0.00 |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
84.56M
Minimum
Jun 2019
165.50M
Maximum
Dec 2022
133.59M
Average
139.08M
Median
Accounts Receivable (Quarterly) Benchmarks
NovaBay Pharmaceuticals Inc | 0.734M |
Palatin Technologies Inc | 0.00 |
iBio Inc | -- |
Theriva Biologics Inc | -- |
Oragenics Inc | -- |